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Aims The aim of this study was to investigate the clinical picture and outcome of cardiogenic shock and to develop a risk
prediction score for short-term mortality.
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Methods
and results
The CardShock study was a multicentre, prospective, observational study conducted between 2010 and 2012.
Patients with either acute coronary syndrome (ACS) or non-ACS aetiologies were enrolled within 6 h from detection
of cardiogenic shock defined as severe hypotension with clinical signs of hypoperfusion and/or serum lactate
>2mmol/L despite fluid resuscitation (n = 219, mean age 67, 74% men). Data on clinical presentation, management,
and biochemical variables were compared between different aetiologies of shock. Systolic blood pressure was on
average 78 mmHg (standard deviation 14 mmHg) and mean arterial pressure 57 (11) mmHg. The most common
cause (81%) was ACS (68% ST-elevation myocardial infarction and 8% mechanical complications); 94% underwent
coronary angiography, of which 89% PCI. Main non-ACS aetiologies were severe chronic heart failure and valvular
causes. In-hospital mortality was 37% (n = 80). ACS aetiology, age, previous myocardial infarction, prior coronary
artery bypass, confusion, low LVEF, and blood lactate levels were independently associated with increased mortality.
The CardShock risk Score including these variables and estimated glomerular filtration rate predicted in-hospital
mortality well (area under the curve 0.85).
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Conclusion Although most commonly due to ACS, other causes account for one-fifth of cases with shock. ACS is independently
associated with in-hospital mortality. The CardShock risk Score, consisting of seven common variables, easily stratifies
risk of short-term mortality. It might facilitate early decision-making in intensive care or guide patient selection in
clinical trials.
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Introduction
Cardiogenic shock is a severe state of systemic hypoperfusion due
to cardiac dysfunction, often resulting in multiorgan failure. The
mortality, both in-hospital and overall, is unacceptably high.
Since the majority of cardiogenic shock is caused by acute
myocardial infarction (MI), most of the data are derived from
registries of patients with MI. However, only 5–8% of patients in
these registries present with shock.1–4 Almost two decades have
passed since the completion of the SHOCK trial, the landmark
trial that established the role of early coronary revascularization in
MI patients with shock.5 Subsequently, thrombolytic therapy and
coronary artery bypass grafting (CABG) have been replaced by
primary PCI as the first-line management.6–8 Recent reports on
improving outcome in cardiogenic shock may reflect this change in
management strategy.2,3
In the recently published IABP-SHOCK II, the largest random-
ized trial in cardiogenic shock to date, only patients with MI were
included.9 Though several cardiac emergencies other than acute
coronary syndromes (ACS) may cause shock, contemporary data
on unselected patients with cardiogenic shock are lacking.10,11
Accordingly, analysis of the clinical presentation and management
of patients with cardiogenic shock in the modern era is neces-
sary for development of new therapeutic approaches and for more
accurate risk stratification in this complex syndrome. Moreover,
there is an obvious clinical need for a simple tool for risk pre-
diction to aid in the urgent and critical task of selecting proper
management, including targeting the most appropriate candidates
for advanced therapies. Besides, a risk classification tool would
be valuable for including more homogenous patient populations in
clinical trials as well as for assessing the case mix in different hospi-
tals in order to carry out proper benchmarking and epidemiological
evaluations.
Therefore, we conducted a prospective, observational multi-
centre and multinational study, including the whole spectrum of
aetiologies of cardiogenic shock. The aim of the CardShock study
was to investigate the aetiology, clinical and biochemical charac-
teristics, as well as management and prognosis of this medical
emergency. In particular, we sought to recognize potential differ-
ences in clinical picture and outcome between patients with and
without ACS as aetiology, and to develop a risk prediction tool for
mortality in cardiogenic shock that could be applied shortly after
presentation in the emergency department or hospital admission.
Methods
The CardShock study (NCT01374867 at www.clinicaltrials.gov) is
a European prospective, observational multicentre and multinational
study on cardiogenic shock. Patients were recruited between October
2010 and 31 December 2012 from emergency departments, cardiac
and intensive care units, as well as catheter laboratories in nine tertiary
hospitals from eight countries.
Inclusion criteria and data collection
The study enrolled consecutive patients aged over 18 years within
6 h from identification of cardiogenic shock. In addition to an acute ..
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.. cardiac cause, the inclusion criteria required systolic blood pressure
to be <90mmHg (after adequate fluid challenge) for 30min or there
to be a need for vasopressor therapy to maintain systolic blood
pressure >90mmHg and signs of hypoperfusion (altered mental sta-
tus/confusion, cold periphery, oliguria <0.5mL/kg/h for the previous
6 h, or blood lactate >2mmol/L). Exclusion criteria were shock caused
by ongoing haemodynamically significant arrhythmias or after cardiac
or non-cardiac surgery.
The aetiology of cardiogenic shock was determined by local inves-
tigators. ACS aetiology was defined as shock caused by MI [with
(STEMI) or without ST-elevation (non-STEMI)]. Echocardiography was
performed per protocol at study entry. Creatinine, C-reactive protein
(CRP), high-sensitivity troponin T (hsTnT), and NT-proBNP (Roche
Diagnostics, Basel, Switzerland) were analysed centrally from blood
samples stored at −80 ∘C. Arterial blood lactate and pH were anal-
ysed locally. Estimated glomerular filtration rate (eGFR) was calculated
from creatinine values using the CKD-EPI (Chronic Kidney Disease Epi-
demiology Collaboration) equation.12 Patients were treated according
to local practice, and treatment and procedures were registered. The
primary endpoint was all-cause in-hospital mortality. Vital status dur-
ing follow-up was determined through direct contact with the patient
or next of kin, or through population and hospital registers. The study
was approved by local ethics committees and conducted in accordance
with the Declaration of Helsinki.
Statistical analysis
Results are presented as numbers (n) and percentages (%), means
and standard deviations (SD), or median and interquartile range (IQR)
for variables with a skewed distribution. Between-group comparisons
were performed using Student’s t-test or Mann–Whitney U-test, as
appropriate. Differences in mortality were assessed by 𝜒2 or by
drawing Kaplan–Meier survival curves which then were compared with
the log-rank test.
Logistic regression analysis was used to identify variables associ-
ated with in-hospital mortality. Based on significant association with
outcome on univariate analysis (with a P-value <0.2 accepted for reten-
tion), multivariable logistic regression modelling was performed. Age,
gender, and a variable accounting for differences between centres were
always included in the multivariable models. Independent predictors of
in-hospital mortality were identified through multiple testing. Variables
with P> 0.1 in adjusted analyses were not retained in the final model.
Goodness-of-fit was assessed by the Hosmer–Lemeshow test. Results
from the regression analyses are presented as odds ratios (ORs) with
95% confidence intervals (CIs).
A risk prediction model for in-hospital mortality was constructed
based on variables independently associated with all-cause death in the
CardShock study. The discriminative ability of the risk prediction model
was assessed by the area under the receiver operating characteristic
(ROC) curve (AUC) or c-statistic. The performance of the prediction
model and the final CardShock risk Score were then compared with
a previously published scoring system from the SHOCK trial13 and
APACHE II score,14 and further validated in an external cohort
(n= 384) from the IABP-SHOCK II trial (see also Supplementary
material online, Appendix 1).9
Finally, seven categorical parameters were included in the Card-
Shock risk Score, giving a maximum of nine points. The distribution
of the population and predicted and observed mortality within risk
categories were calculated. A two-sided P-value <0.05 was regarded
as statistically significant. SPSS 21.0 statistical software (IBM Corp,
Armonk, NY, USA) was used in all statistical analyses.
© 2015 The Authors
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Table 1 Baseline characteristics of the study population
Characteristic All (n= 219) ACS (n= 177) Non-ACS (n= 42) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 67 (12) 68 (11) 62 (15) 0.03
Age >75 years, n (%) 54 (25) 45 (25) 9 (21) 0.6
Women, n (%) 57 (26) 39 (22) 18 (43) 0.006
BMI, median (IQR) 26.5 (24.2–29.0) 26.6 (24.2–29.0) 25.8 (23.0–29.4) 0.3
Medical history, n (%)
Coronary artery disease 76 (35) 59 (334) 17 (40) 0.4
Previous myocardial infarction 54 (25) 42 (24) 12 (29) 0.5
Prior revascularization
PCI 32 (15) 28(16) 4 (10) 0.3
CABG 16 (7) 10 (6) 6 (14) 0.05
Heart failure 36 (16) 16 (9) 20 (48) <0.001
Hypertension 132 (60) 111 (63) 21 (50) 0.13
Diabetes 62 (28) 56 (32) 6 (14) 0.03
Asthma/COPD 25 (11) 18 (10) 7 (17) 0.2
Renal insufficiency 25 (11) 14 (8) 11 (26) 0.001
Atrial fibrillation 32 (15) 17 (10) 15 (36) <0.001
Stroke/TIA 20 (9) 14 (8) 6 (14) 0.2
Smoker 87 (40) 78 (44) 9 (21) 0.01
Data are presented as numbers and percentages (%), means (standard deviation), and median (IQR).
P-values are for the difference between ACS and non-ACS groups.
ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass grafting; IQR, interquartile range; TIA, transient ischaemic attack
Results
Study population
A total of 219 patients were included in the study. Twenty-four per
cent of them had shock at presentation to hospital, whereas 62%
developed shock within the first 24 h from admission. Only 14%
developed shock after 24 h from admission.
Baseline characteristics are described in Table 1. Briefly, mean
age was 67 (12) years, and 74% were men. The main co-morbidities
were hypertension (60%), CAD (35%), and diabetes (28%), while
a history of previous MI (25%) or heart failure (16%) was less
common. At detection of shock, systolic blood pressure was on
average 78 (14) mmHg, diastolic blood pressure 47 (10) mmHg,
mean arterial pressure 57 (11) mmHg, and heart rate 90 (28)
b.p.m. Sinus rhythm was present in 170 (78%) patients and AF
in 34 (16%). Of those 34 patients, 18 had no previous history
of AF. Pacemaker rhythm was present in five (2.3%) patients. Ten
(4.6%) patients had other haemodynamically non-significant rhythm
(five junctional rhythm, two nodal rhythm, two ventricular rhythm,
and one supraventricular tachycardia). Each of the clinical signs
of hypoperfusion was observed very frequently (Table 2). Left
ventricular systolic function was impaired at baseline, with mean
LVEF of 33% (14%). The most common cause of shock was ACS
(81%; n= 177), with non-ACS causes accounting for the remaining
19% (n= 42).
The majority of ACS patients (n= 148; 68% of all patients)
presented with STEMI whereas 19 (9%) had a mechanical com-
plication of MI including 6 ruptures of papillary muscle, 10 of
ventricular septum and 3 of LV free wall. Non-ACS causes con-
sisted mainly of worsening of chronic heart failure (11%), valvular .
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. and other mechanical causes (6%), stress-induced cardiomyopathy
(Tako-Tsubo; 2%), and myocarditis (2%).
Acute coronary syndrome and non-acute
coronary syndrome causes of cardiogenic
shock
The characteristics and clinical picture of cardiogenic shock
patients with and without ACS are compared in Tables 1 and 2.
The prevalence of history of CAD or previous MI was similar
in both groups. Patients with non-ACS, in whom previous his-
tory of heart failure was more frequent, had low TnT levels but
significantly higher levels of NT-proBNP at baseline compared
with ACS patients. Levels of TnT on admission were a good
discriminator between patients with and without ACS (AUC 0.91,
95% CI 0.86–0.96; P< 0.001). Nevertheless, although non-ACS
shock comprised a variety of aetiologies, the clinical presentation
and medical treatment were very similar in both patients groups
(Table 2; Supplementarty material online, Table S1). Subjects in the
non-ACS subgroup were on average younger with a high propor-
tion of women. AF was more common in non-ACS patients both
in the medical history (see Table 2) and as rhythm at presentation
(21% vs. 14% in ACS patients, P= 0.2). Nevertheless, new-onset
(no known history of) AF was actually observed more frequently
in ACS patients (n=17) compared with non-ACS patients (n=1).
Pneumonia was diagnosed in six (14%) non-ACS patients, and
other infections in five (12%). Baseline LVEF was similar in both
groups, but moderate to severe mitral regurgitation was observed
in nearly a half of non-ACS shock patients.
© 2015 The Authors
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Table 2 Comparison of clinical presentation, biochemistry and mortality of all cardiogenic shock patients and of
those with and without acute coronary syndromes
Characteristic All (n= 219) ACS (n= 177) Non-ACS (n= 42) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Systolic blood pressure, mmHg 78 (14) 77 (14) 79 (11) 0.6
Diastolic blood pressure, mmHg 47 (10) 46 (11) 48 (9) 0.3
Mean arterial pressure, mmHg 57 (11) 56 (11) 59 (9) 0.14
Heart rate, b.p.m. 90 (28) 89 (29) 96 (24) 0.1
Sinus rhythm 170 (78) 140 (79) 30 (71) 0.3
Clinical findings, n (%)
Cold periphery 207 (95) 166 (94) 41 (98) 0.4
Confusion 148 (68) 126 (71) 22 (52) 0.04
Oliguria 121 (55) 98 (55) 24 (57) 0.7
Lactate >2mmol/L 155 (71) 126 (71) 29 (69) 0.9
Resuscitated from cardiac arrest 62 (28) 55 (31) 7 (17) 0.06
Time from detection of shock to study inclusion, min 105 (0–210) 100 (0–195) 120 (28–240) 0.2
Baseline echocardiography
LVEDD (mm) 52 (9) 51 (8) 59 (11) <0.001
LVEF (%) 33 (14) 34 (14) 30 (15) 0.12
LVEF <40% 135 (65) 107 (63) 28 (72) 0.3
Mitral regurgitation (moderate or severe), n (%) 73 (35) 54 (32) 19 (48) 0.07
Biochemistry
Blood haemoglobin (g/L) 128 (22) 129 (22) 127 (21) 0.7
Sodium (mmol/L) 137 (5) 137 (5) 136 (7) 0.3
Potassium (mmol/L) 4.2 (0.8) 4.2 (0.8) 4.4 (0.9) 0.3
Arterial blood lactate (mmol/L) 2.8 (1.7–5.8) 3.0 (1.8–5.8) 2.6 (1.3–5.8) 0.3
Arterial blood pH 7.30 (7.20–7.40) 7.30 (7.20–7.40) 7.30 (7.20–7.40) 0.2
hsTnT (ng/L) 2190 (388–5418) 2873 (1056–7555) 104 (40–389) <0.001
NT-proBNP (pg/mL) 2710 (585–9434) 1948 (472–9093) 6431 (2522–14064) 0.006
Creatinine (mmol/L) 104 (78–140) 101 (79–139) 111 (64–162) 0.8
eGFR (mL/min/1.73m2) 61 (41–87) 61 (42–86) 61 (32–97) 0.8
CRP (g/L) 16 (4–54) 13 (4–48) 29 (7–91) 0.03
In-hospital length of stay, days 12 (7–25) 11 (6–27) 16 (10–24) 0.11
In-hospital mortality, n (%) 80 (37) 70 (40) 10 (24) 0.06
Data are presented as numbers and percentages (%), mean (standard deviation), and median (IQR).
P-values are for the difference between ACS and non-ACS groups.
ACS, acute coronary syndrome; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula;
hsTnT, highly sensitive troponin T; IQR, interquartile range; LVEDD, left ventricular end-diastolic diameter.
Management and procedures are detailed in Supplementarty
material online, Table S1. Overall, 85% of patients received a
vasopressor (norepinephrine, epinephrine, dopamine, vasopressin,
or terlipressin) and 66% an inotrope (dobutamine, levosimendan,
milrinone, or enoximone). The majority of patients received a
vasopressor–inotrope combination. Only vasopressors were given
to 29% of patients and only inotropes to 10%. Rates of vasopressor
and inotrope support were also comparable in ACS and non-ACS
groups. Almost all patients (94%) with ACS aetiology underwent
coronary angiogram, and of these 89% underwent PCI. Of the
remaining 11%, seven patients underwent surgical correction of
mechanical complication, three had only CABG, and nine ACS
patients were treated conservatively.
Mortality and predictors of hospital
death
There were 70 deaths (32%) in the intensive or cardiac care units,
and a total of 80 deaths (37%) during hospital stay. Non-ACS .
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. patients had a more favourable course compared with patients with
ACS aetiology (Table 2). Univariate predictors of in-hospital mortal-
ity are shown in Supplementarty material online, Table S2. Adjusted
ORs for factors associated with mortality are shown in Table 3.
Interestingly, ACS was independently associated with worse prog-
nosis (OR 7.4, 95% CI 1.9–29.8; P= 0.005), suggesting clearly bet-
ter survival in patients with other causes of cardiogenic shock. The
Kaplan–Meier survival curve stratified by ACS aetiology is shown
in Figure 1.
The CardShock risk Score for prediction
of in-hospital mortality
Using the variables from Table 3, we created a prediction model
for in-hospital mortality. The prediction model exhibited excellent
discrimination, with an AUC of 0.85 (95% CI 0.79–0.90; P< 0.001)
for hospital mortality compared with an AUC of 0.76 (95% CI
0.69–0.83) for the Sleeper score from the SHOCK trial (Figure 2).13
The prediction model was validated in the IAPB-SHOCK II trial
© 2015 The Authors
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Table 3 Predictors of in-hospital mortality in
cardiogenic shock
Variable Adjusted OR
(95% CI)
P-valuea
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prior CABG 10.7 (1.8–64.7) 0.01
ACS aetiology 7.4 (1.9–29.8) 0.005
Confusion 3.0 (1.1–8.1) 0.03
Previous myocardial
infarction
3.2 (1.2–8.2) 0.02
Blood lactate (per mmol/L) 1.4 (1.2–1.6) <0.001
LVEF (per % decrease) 1.06 (1.02–1.09) 0.001
Age (per year) 1.04 (1.00–1.08) 0.08
Systolic blood pressure (per
mmHg decrease)
1.03 (0.99–1.06) 0.09
The multivariable model included all variables in the table and further contained
gender and a variable accounting for possible differences between centres.
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CI,
confidence interval; OR, odds ratio.
aHosmer–Lemeshow P-value 0.4 for in-hospital mortality.
Figure 1 Kaplan–Meier in-hospital survival curves for cardio-
genic shock patients with (red line) and without (blue line) acute
coronary syndrome aetiology.
population and further refined to the CardShock risk Score which
also included eGFR as a variable (Supplementarty material online,
Appendix 1).
Finally, the CardShock risk Score consists of seven variables giv-
ing a maximum of nine points (Table 4). It had similar discrimination
to the prediction model with an AUC of 0.85 (95% CI 0.80–0.90;
P< 0.001) (Figure 2; Supplementarty material online, Figure S1). For
comparison, the APACHE II score14 had an AUC of 0.76 (95%
CI 0.67–0.84) in the total CardShock population (Figure 2). In
the validation cohort, the CardShock risk Score (AUC 0.71, 95%
CI 0.66–0.76) also had better predictive performance than the
Sleeper score (Figure 2). In addition, the CardShock risk Score
performed well in both ACS (AUC 0.83, 95% CI 0.77–0.89) and
non-ACS (AUC 0.94, 95% CI 0.87–1.0; P< 0.001 for both) groups
(Supplementarty material online, Figure S2). Again, in the ACS ..
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.. group, the AUC of the Sleeper score was 0.75 (95% CI 0.68–0.83)
and that of the APACHE II score was 0.75 (95% CI 0.66–0.84).
The distribution of the study population across cumulative points
in risk score and the stepwise increase in both predicted and
observed mortality with higher scores are shown in Figure 3. The
population can be classified according to the CardShock risk Score
into low (scores 0–3), intermediate (scores 4–5), and high (scores
6–9) risk groups with observed mortality of 8.7, 36 and 77%,
respectively.
Discussion
The CardShock study is by far the largest European prospective,
observational multicentre and multinational study on cardiogenic
shock, describing a contemporary cohort of unselected patients
with cardiogenic shock covering a broad spectrum of aetiolo-
gies. STEMI and other forms of ACS are still the leading causes
of cardiogenic shock. Almost all of these patients undergo coro-
nary angiogram and percutaneous or surgical revascularization.
Nevertheless, one-fifth of shock cases have an aetiology other
than ACS. Interestingly, our study clearly suggests that despite
having similar clinical presentation and severity, ACS aetiology is
independently associated with increased mortality compared with
non-ACS. Finally, the CardShock risk Score, consisting of seven
easily recognizable clinical variables, shows good performance in
early risk stratification and prediction of short-term mortality in
cardiogenic shock.
For many patients, shock was the first manifestation of heart
disease. Hypertension and diabetes were commonly present, but
only a minority had previous ischaemic heart disease or a history
of heart failure, as also described in other cohorts.4,9 Confusion
and elevated blood lactate at presentation indicate the presence
of severe systemic hypoperfusion and organ dysfunction, and were
independently associated with higher risk of death in the present
study. Still, the clinical significance of confusion is often underes-
timated in daily clinical practice. An increase in blood lactate is
a well-known prognostic factor in critical illness. It derives from
increased lactate production in hypoperfusion states or decreased
lactate clearance that may also be secondary to liver dysfunction.
Indeed, multiorgan damage and failure, or systemic pathways acti-
vated in the state of cardiogenic shock, have been suggested to
contribute to the detrimental prognosis.15–17
While the literature is largely focused on cardiogenic shock
secondary to MI, a significant proportion of reported cases have
aetiologies other than ACS. These disorders are heterogeneous,
ranging from advanced severe heart failure to temporary cardiac
disturbances, sometimes correctable by interventions or even
self-limiting.10,11 Consequently, other causes should be actively
evaluated, especially in the absence of STEMI.
There are some interesting observations regarding management.
Following the publication of the landmark SHOCK trial, angiog-
raphy and early invasive revascularization became the preferred
approach to shock caused by ACS.5 Moreover, it should be an
unambiguous goal to avoid prolonged hypoperfusion and develop-
ment of multiorgan injury and failure. Vasoactive medications and
© 2015 The Authors
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Figure 2 C-statistics for prediction of in-hospital mortality of the CardShock risk Score. C-statistics (lines represent the 95% confidence
interval) of the CardShock risk Score and the Sleeper score (SHOCK trial and registry13) in the CardShock (derivation) and IABP-SHOCK II
(validation) cohorts. C-statistics for the APACHE II score (Knaus et al.14) in the CardShock cohort are shown for comparison.
Table 4 The CardShock risk Score for risk prediction
of in-hospital mortality in cardiogenic shock
Variable CardShock risk Score
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age >75 years 1
Confusion at presentation 1
Previous MI or CABG 1
ACS aetiology 1
LVEF <40% 1
Blood lactate
<2mmol/L 0
2–4mmol/L 1
>4mmol/L 2
eGFRCKD-EPI
>60mL/min/1.73m2 0
30–60mL/min/1.73m2 1
<30mL/min/1.73m2 2
Maximum points 9
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; MI,
myocardial infarction; eGFRCKD-EPI, estimated glomerular filtration rate by the
Chronic Kidney Disease Epidemiology Collaboration formula.
inotropes are still required in most patients with severe circula-
tory shock, although their benefit is uncertain, with concerns about
safety.15,18,19
Intra-aortic balloon support was still rather common in the
present study. However, the IABP-SHOCK II trial which showed
the lack of survival benefit of intra-aortic balloon treatment in
MI complicated by shock was published shortly before the end
of the recruitment of the present study.9 The infrequent use
of ventricular assist devices perhaps reflects difficulty in patient .
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. selection. Considering the current high mortality rate, early selec-
tion of patients for advanced management including rational use
of mechanical assist devices seems plausible, but remains to be
proven.
The short-term mortality of ∼40% in the present study is in line
with that in the recent IABP-SHOCK II trial.9 Improving survival
has been observed during the past two decades, attributed to the
introduction of routine use of percutaneous revascularization in
STEMI and modern intensive care.2,3,20 Nevertheless, survival in
cardiogenic shock is still dismal.
Acute coronary syndrome was an independent predictor of
in-hospital mortality despite very high rates of revascularization
procedures. Since aetiologies other than ACS have been excluded
from most studies of cardiogenic shock, this finding is, to our
knowledge, novel. ACS with shock is associated with irreversible
myocardial damage of significant magnitude, which often triggers
inflammatory and other systemic responses. Previous MI or CABG,
which may reflect a more extensive and severe ischaemic heart
disease and limited reserves for recovery, were also strongly
predictive of poor outcome. Interestingly, the clinical presentation,
the prevalence of previous CAD, as well as mean LVEF were similar
between patients with and without ACS.
The CardShock risk Score incorporated common clinical vari-
ables for prediction of in-hospital mortality. These parameters are
readily available from clinical assessment, and the score can be
calculated within a very short time after presentation of shock,
which facilitates early risk stratification. From the SHOCK trial
and registry data, Sleeper et al. developed a scoring system with
clinical predictors of short-term outcome.13 Several of the vari-
ables in this scoring system are also found in our model, i.e.
older age, signs of peripheral hypoperfusion, cerebral dysfunction
© 2015 The Authors
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Figure 3 The CardShock risk Score. (A) Predicted risk of death with the CardShock risk Score. Boxplots show the median with the
interquartile range of calculated predicted risk of death in each of the CardShock risk categories. Lines constitute the 10th and 90th percentile.
The asterisk and circle are outliers. The x-axis depicts the cumulative points from the CardShock risk Score and the y-axis the predicted risk from
the multivariable model. (B) Distribution of the population (red line) and in-hospital mortality (%; blue bars) according to the cumulative points
from the CardShock risk Score. The population can be classified according to the CardShock risk Score into low (scores 0–3), intermediate
(scores 4–5), and high (scores 6–9) risk groups with observed mortalities of 8.7, 36, and 77%, respectively.
(though defined as a much more severe form, i.e. anoxic brain
injury in the SHOCK trial), LVEF, and prior CABG.13 However,
arterial blood pH was not an independent predictor of risk. The
independent associations of elevated blood lactate and altered
mental status with mortality in the IABP-SHOCK II trial empha-
size the importance of hypoperfusion for prognosis.21 Prior MI
or CABG were not associated with outcome in IABP-SHOCK
II, but the prevalence was low. Incorporating a measure of renal
function in the risk prediction model seems clinically justified
and improved the performance of the score in the validation
cohort.13,21–23 Severity of LV systolic dysfunction also correlates
with outcome in cardiogenic shock.21,24 Indeed, echocardiography
is clearly indicated in every patient with shock to assess ventricu-
lar and valvular function and to detect mechanical complications.
In contrast to what has been described in other populations of
critically ill patients, heart rate was not a predictor of risk in this
population.25
In everyday clinical practice, older age is often an exclusion
criterion for advanced therapies such as prolonged intensive care,
cardiac transplantation, or the use of mechanical assist devices.
However, in light of our data, though older age increases early
mortality, it is just one of the predictors of outcome. Thus,
in addition to age, both medical history and several factors on
admission have to be included in individual decision-making.
A central aim of the study was to develop a practical tool
for risk assessment of short-term mortality for patients with
cardiogenic shock. Prognostic risk scores for unselected acute
heart failure populations cannot be applied to cardiogenic shock,
which represents only 2–4% of cases with acute heart failure.
Scores assessing organ dysfunction and disease severity in the
critically ill (APACHE, SAPS, MODS, and SOFA) have been shown ..
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.. also to predict mortality in patients with cardiogenic shock, but
were primarily developed for assessing disease severity in patients
admitted to the Intensive Care Unit (ICU).16,17 Moreover, in this
study, the predictive performance of APACHE II was similar to the
Sleeper score and poorer than the novel CardShock risk Score.
The contemporary CardShock risk Score is easy to assess,
simple to calculate, and shows good performance for risk predic-
tion of short-term mortality, both in the original CardShock and
in the validation cohort. The risk score demonstrated good dis-
crimination of poor outcome in both ACS and non-ACS patients.
This ideally makes the score useful also for patients with severe
forms of cardiomyopathies. In addition, in ACS patients, neither
the APACHE II score nor the Sleeper score performed as well
as the CardShock risk Score. The results show the strength and
utility of the CardShock risk Score, which classifies patients in risk
categories, with a clear and stepwise increase in mortality for the
majority of the population with cardiogenic shock. We believe that
the risk score might aid in selection of management strategies.
Proper risk categorization may also be of importance in planning
treatment trials to identify optimally patients that might benefit
from current and novel therapies.
When the APACHE II score was introduced in 1985, it was
advocated to be combined with an accurate description of disease
and thereby to be used for prognostic stratification of a wide range
of ill patients and for assisting investigators comparing the success
of new or differing forms of therapy.14 The CardShock risk Score
can have similar applications.
The aetiology, clinical presentation, and management of cardio-
genic shock differ in several ways from those of a mixed ICU pop-
ulation. Thus, it seems warranted to have a specific risk score for
patients with cardiogenic shock. The CardShock risk Score is a
© 2015 The Authors
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simple tool for classification of patients with clearly different mor-
tality risks. In comparison, the score from the SHOCK trial is more
complex to calculate, and was developed from a cohort recruited
almost 20 years ago.13 As populations change and new diagnostic,
therapeutic, and prognostic techniques become available, scoring
systems need to be updated.26
The role of a risk score can be approached from several dis-
tinct views. In epidemiological studies, the CardShock risk Score
would give a uniform description of severity and mortality risk
across the population. Secondly, the absence of evidence-based
therapies in cardiogenic shock is striking. Even most of the cur-
rent therapies would need to be proven safe and effective. From
the regulatory and clinical aspects, appropriate patient selec-
tion for randomized trials is crucial. In order to recruit a more
homogenous population, patients have to be categorized accord-
ing to the inherent risk of the syndrome. In a putative treat-
ment trial, the CardShock risk Score could be used for target-
ing the study to include patients with intermediate to high, but
not low or extremely high, mortality risk. Thirdly, it is obvi-
ous that novel, costly therapies with potentially high compli-
cation rates need to be targeted at pre-specified populations
with a certain risk profile in order to achieve most benefit and
cost-effectiveness. Finally, a systematic characterization of the pop-
ulation would enable benchmarking of different facilities as well
as cost-effectiveness analyses. A score allows more uniform com-
parison of management strategies between different centres and
countries.
There are some limitations that should be acknowledged. For
a prospective cohort in cardiogenic shock, the CardShock study
included a reasonable number of patients, but the statistical CIs
are sometimes wide. Since most patients had ACS aetiology,
the non-ACS group is heterogeneous and of limited size. There
was no adjudication of the diagnosis and aetiology of cardio-
genic shock. However, there were unambiguous clinical criteria
for cardiogenic shock, and ACS was defined using current diag-
nostic criteria including electrocardiographic changes in patients
with STEMI. In addition, angiographic findings were available in
most of the patients for further confirmation of the aetiology
though a centralized analysis of coronary angiograms was not
performed for the present analysis. In older studies, the cardiac
index and pulmonary artery wedge pressure were elemental for
the definition of cardiogenic shock.5 However, in the present
study only 39 patients (17%) had a pulmonary artery catheter
at baseline, while in some patients it was inserted only later.
This limits the comparability of our results with the oldest stud-
ies. Validation of the CardShock risk Score was performed in a
large contemporary population that included only ACS patients.
A larger prospective validation cohort of unselected cardiogenic
shock patients including a higher number of non-ACS cases would
have been of great value. However, such a cohort is not currently
available.
Conclusion
Cardiogenic shock is a state of severe systemic hypoperfusion due
to cardiac failure characterized by haemodynamic compromise and ..
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.. a common need for vasoactive medication, and is still associated
with high in-hospital mortality. While STEMI or mechanical compli-
cations of MI are the most common causes of cardiogenic shock,
20% of patients have non-ACS aetiology. Despite current active
use of early invasive revascularization, shock caused by ACS is
associated with significantly higher mortality risk compared with
other causes of cardiogenic shock. The CardShock risk Score
incorporating seven easily available variables shows good discrimi-
nation and can be used for early prediction of in-hospital mortality.
By objectively categorizing patients into discrete risk groups the
score might aid in clinical decision-making, patient selection in clin-
ical trials, as well as comparing the case mix of different patient
populations.
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